Showing 4581-4590 of 5957 results for "".
- EssilorLuxottica Closes Acquisition of Walman Opticalhttps://modernod.com/news/essilorluxottica-closes-acquisition-of-walman-optical/2480668/EssilorLuxottica announces today the closing of its acquisition of U.S.-based lab network Walman Optical, a leading lab partner to vision care practices around the country. First announced in March 2021, the acquisition will draw on EssilorLuxottica’s focus on product and service innovation
- Alpine and Shamir Extend Strategic Partnership Into Esports Worldhttps://modernod.com/news/alpine-and-shamir-extend-strategic-partnership-into-esports-world/2480654/Shamir has announced a multi-year extension to its partnership with Alpine F1 Team, becoming the optical performance partner of Alpine Esports Team. Shamir will provide ophthalmic assessments and improvement of gaming performance, and endurance through cutting edge lenses and
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Quantel Medical Launches C.STIM, a New Generation IPL System for Dry Eyehttps://modernod.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/Quantel Medical announced the launch of C.STIM IPL system. Based on intense pulsed light technology, C.STIM is the new generation of IPL designed to treat the root causes of dry eyes: meibomian gland dysfunction, inflammation, and demodex. “Thanks to the unique